Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

ress in advancing programs within its late-stage development pipeline. These programs have significant potential to drive the company's growth beyond 2011.

Mozobil(TM) (plerixafor) for stem-cell transplantation

-- Genzyme plans to file mid year for U.S. and European approval for

Mozobil's use in treating patients with multiple myeloma and patients

with lymphoma. The company expects to launch the product in the United

States early next year upon approval and to rapidly expand the

product's availability around the world. The company anticipates peak

annual sales of the product in the transplant setting of $400 million.

Mozobil is an innovative product intended to enhance the mobilization

of stem cells for transplantation in patients with lymphoma and

multiple myeloma. In two pivotal clinical studies, Mozobil showed the

ability to quickly and predictably prepare cancer patients for a

transplant to treat their disease. Genzyme is also exploring

additional indications for Mozobil, including its potential use in

chemosensitization procedures.

Clolar for adult AML

-- Clolar is approved in the United States and Europe for the treatment of

acute lymphoblastic leukemia in relapsed and refractory pediatric

patients. Genzyme is developing the product for use globally as a

first-line therapy for the treatment of adult acute myeloid leukemia

(AML) and myelodysplastic syndromes, significantly larger indications

that the company estimates will drive peak annual sales of the product

to approximately $600 million. The company intends to submit a

supplemental new drug application in the United States later this year

to include an adult AML indication. This application will be based on

results from the CLASSIC II clinical trial involving older adult AML

<
'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2014)... , July 18, 2014  Neogen Corporation (Nasdaq: ... Snyder , Neogen,s chief operating officer and president, has ... will work as a consultant going forward on special ... Snyder has been in this position since September 2013. ... by James Herbert , who has been Neogen,s ...
(Date:7/18/2014)... That is, most of the atoms in our ... in the outer parts of atoms equals the number ... one or more electrons are plucked away from the ... pull from the nucleus. This enhanced pull, causing ... electrons are less vulnerable to the distractions of their ...
(Date:7/18/2014)... , July 18, 2014  Neurotrope, Inc. (OTCQB: NTRP) ... of Directors appointed Co-Chairmen Charles S. Ramat ... on an interim basis, effective immediately. Messrs. Ramat and ... no longer Chief Executive Officer of Neurotrope Bioscience, Inc., ... and whose employment agreement with Neurotrope Bioscience Inc. terminated ...
(Date:7/18/2014)... Emerging Nuclear Power Countries - Market Forecast, ... , The latest report from GlobalData, Emerging Nuclear Power ... to 2030 covers the emerging nuclear market and the ... on key market players and their global market share. ... across the world has also been estimated. , To ...
Breaking Biology Technology:Highly charged ions 2Highly charged ions 3Highly charged ions 4Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 2Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 3Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 4Emerging Nuclear Power Countries - Market Forecast, Key Companies and Development Analysis, Size, Share, Growth, Trend to 2030 2Emerging Nuclear Power Countries - Market Forecast, Key Companies and Development Analysis, Size, Share, Growth, Trend to 2030 3
... electrical hair that lets them link up in ... Southern California biophysicist and his collaborators. The ... and share energy in part through electrically conducting ... the first measurement of electron transport along biological ...
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) announced ... product candidate, fidaxomicin, will be presented ... Disease Society of America (IDSA) to be held at ... on October 21-24, 2010. (Logo: ...
... N.J. Physicists at Rutgers University have discovered new ... and inexpensive plastic solar cells for pollution-free electricity production. ... in an upcoming issue of the journal Nature ... of light can travel on the order of a ...
Cached Biology Technology:Microbial hair: It's electric 2Microbial hair: It's electric 3Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting 2Rutgers discovery paves way for development of efficient, inexpensive plastic solar cells 2
(Date:7/21/2014)... has issued a high health risk warning for Yellowknife ... region due to forest fires. Currently 160 wildfires ... plans for evacuation since these fires are endangering people ... area recently comes with mixed results. The rains ... to start others. , This year the Northern Territories ...
(Date:7/21/2014)... School of Medicine-led study suggests that parents of obese ... consequences of childhood weight gain or the importance of ... healthy weight. , The study is published online in ... Dietetics . , "Parents have a hard time changing ... author Kyung Rhee, MD, and an assistant adjunct professor ...
(Date:7/21/2014)... Aqua satellites detected 154 hotspots in areas across Riau ... fires had increased again following a decline in rainfall. ... was far higher than what had been reported one ... The hotspots were scattered in six regencies and municipalities, ... Smoke and the related haze it creates could potentially ...
Breaking Biology News(10 mins):Parents rank their obese children as 'very healthy' 2
... A newly identified defect in a DNA repair system might ... a key chemotherapy drug, possibly putting them at greater risk ... by St. Jude Children,s Research Hospital scientists. The ... acute lymphoblastic leukemia (ALL) patients who are at higher risk ...
... compound tested by UT Southwestern Medical Center investigators destroys several ... 30 million people in the worldwide pandemic of 1918. ... of a human antiviral protein - could potentially be developed ... that tends to mutate into strains resistant to anti-influenza drugs. ...
... [Brown University] Take your time. Hold your horses. ... arguably equal choices, they need time to deliberate. In ... for Parkinson,s disease, that process sometimes doesn,t kick in, ... happens has led scientists to a detailed explanation of ...
Cached Biology News:Newly identified DNA repair defect linked to increased risk of leukemia relapse 2Newly identified DNA repair defect linked to increased risk of leukemia relapse 3Compound kills highly contagious flu strain by activating antiviral protein 2DBS studies show how brain buys time for tough choices 2DBS studies show how brain buys time for tough choices 3
UGT1A7 (E-15)...
... peptide corresponding to the third cytoplasmic loop ... conjugated to KLH. The immunizing peptide has ... gene. Physical form: Solution in phosphate ... azide. Titertest method: IHC (p). ...
... Human Pathogenic Viruses The National ... preserves well characterised, authenticated human ... facility, and NCPV is able ... nucleic acids derived from them, ...
... easy to use Ascent Software ... members of the Ascent microplate ... clear and easy-to-follow approach with ... and highly sophisticated data handling, ...
Biology Products: